Elevated HSPB1 Expression Is Associated with a Poor Prognosis in Glioblastoma Multiforme Patients

Abstract

Background Glioblastoma multiforme (GBM) is a highly aggressive form of brain cancer. This study investigated the clinical predictive value of heat shock protein β1 (HSPB1) in patients with GBM.

Methods A correlation was established between HSPB1 expression and GBM progression using data from The Cancer Genome Atlas (TCGA) dataset, Chinese Glioma Genome Atlas dataset, Gene Expression Omnibus dataset, and Human Protein Atlas database. A survival analysis was conducted and an HSPB1-based nomogram was constructed to evaluate the prognostic value of HSPB1 in patients with GBM.

Results Based on TCGA data mining, we discovered that HSPB1 was significantly elevated in patients with GBM and may reflect their response to immunotherapy. In survival analysis, it appeared to have a predictive role in the prognosis of patients with GBM. Five signaling pathways were significantly enriched in the high HSPB1 expression phenotype according to the gene set enrichment analysis. In addition, a significant association was found between HSPB1 expression and immune checkpoints, tumor immune infiltration, tumor immune microenvironment, and immune cell markers in glioma. Overall, our results suggest that HSPB1 may regulate the function of immune cells, serve as a new immunotherapy target, and predict the response to immunotherapy in patients with GBM.

Conclusion HSPB1 appears to serve as a potential predictor of the clinical prognosis and response to immunotherapy in patients with GBM. It may be possible to identify patients who are likely to benefit from immunotherapy by assessing the expression level of HSPB1.

Keywords

glioblastoma multiforme - heat shock protein β1 - biomarker - immunity - prognosis

Availability of Data and Material

All data generated or analyzed are included in this article and are available from the corresponding author on reasonable request.

Author Contributions

Z.W. was responsible for the design and concept of the study, analysis and visualization, and writing and revision of the article. Z.F., B.X., and Y.G. contributed to article revising and reviewing. Z.X. contributed to the study design and concept, and article reviewing. All the authors approved the final version of the article.

Publikationsverlauf

Eingereicht: 18. Mai 2023

Angenommen: 24. Oktober 2023

Artikel online veröffentlicht:
03. Juli 2024

• References

• 1 Stupp R, Hegi ME, Mason WP. et al; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups, National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10 (05) 459-466
• 2 Ostrom QT, Gittleman H, Liao P. et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. Neuro-oncol 2017; 19 (Suppl. 05) v1-v88
• 3 Virtuoso A, Giovannoni R, De Luca C. et al. The glioblastoma microenvironment: morphology, metabolism, and molecular signature of glial dynamics to discover metabolic rewiring sequence. Int J Mol Sci 2021; 22 (07) 22
• 4 Carrasco-Garcia E, Martinez-Lacaci I, Mayor-López L. et al. PDGFR and IGF-1R inhibitors induce a G2/M arrest and subsequent cell death in human glioblastoma cell lines. Cells 2018; 7 (09) 7
• 5 Cho CF, Farquhar CE, Fadzen CM. et al. A tumor-homing peptide platform enhances drug solubility, improves blood-brain barrier permeability and targets glioblastoma. Cancers (Basel) 2022; 14 (09) 14
• 6 Lechpammer M, Rao R, Shah S. et al. Advances in immunotherapy for the treatment of adult glioblastoma: overcoming chemical and physical barriers. Cancers (Basel) 2022; 14 (07) 14
• 7 McGranahan T, Therkelsen KE, Ahmad S, Nagpal S. Current state of immunotherapy for treatment of glioblastoma. Curr Treat Options Oncol 2019; 20 (03) 24
• 8 Chen Z, Hambardzumyan D. Immune microenvironment in glioblastoma subtypes. Front Immunol 2018; 9: 1004
• 9 Reardon DA, Brandes AA, Omuro A. et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial. JAMA Oncol 2020; 6 (07) 1003-1010
• 10 Amoozgar Z, Kloepper J, Ren J. et al. Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas. Nat Commun 2021; 12 (01) 2582
• 11 Pombo Antunes AR, Scheyltjens I, Duerinck J, Neyns B, Movahedi K, Van Ginderachter JA. Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies. eLife 2020; 9: 9
• 12 Lianos GD, Alexiou GA, Mangano A. et al. The role of heat shock proteins in cancer. Cancer Lett 2015; 360 (02) 114-118
• 13 Zhang R, Tremblay TL, McDermid A, Thibault P, Stanimirovic D. Identification of differentially expressed proteins in human glioblastoma cell lines and tumors. Glia 2003; 42 (02) 194-208
• 14 Wang S, Xiong Y, Zhao L. et al. UCSCXenaShiny: an R/CRAN package for interactive analysis of UCSC xena data. . Bioinformatics 2021
• 15 Uhlén M, Fagerberg L, Hallström BM. et al. Proteomics. Tissue-based map of the human proteome. Science 2015; 347 (6220) 1260419
• 16 Szklarczyk D, Morris JH, Cook H. et al. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res 2017; 45 (D1): D362-D368
• 17 Bader GD, Hogue CW. An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics 2003; 4: 2
• 18 Subramanian A, Tamayo P, Mootha VK. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005; 102 (43) 15545-15550
• 19 Zhou Q, Yan X, Liu W. et al. Three immune-associated subtypes of diffuse glioma differ in immune infiltration, immune checkpoint molecules, and prognosis. Front Oncol 2020; 10: 586019
• 20 Kim JE, Patel MA, Mangraviti A. et al. Combination therapy with anti-PD-1, anti-TIM-3, and focal radiation results in regression of murine gliomas. Clin Cancer Res 2017; 23 (01) 124-136
• 21 Garg AD, Vandenberk L, Van Woensel M. et al. Preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma. OncoImmunology 2017; 6 (04) e1295903
• 22 Ye W, Luo C, Li C, Liu Z, Liu F. CD161, a promising immune checkpoint, correlates with patient prognosis: a pan-cancer analysis. J Cancer 2021; 12 (21) 6588-6599
• 23 Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics 2013; 14: 7
• 24 Bindea G, Mlecnik B, Tosolini M. et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013; 39 (04) 782-795
• 25 Yoshihara K, Shahmoradgoli M, Martínez E. et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun 2013; 4: 2612
• 26 Ostrom QT, Cioffi G, Gittleman H. et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016. Neuro-oncol 2019; 21 (Suppl. 05) v1-v100
• 27 Yaghi NK, Gilbert MR. Immunotherapeutic approaches for glioblastoma treatment. Biomedicines 2022; 10 (02) 10
• 28 M Gagné L, Boulay K, Topisirovic I, Huot MÉ, Mallette FA. L MG. Oncogenic activities of IDH1/2 mutations: from epigenetics to cellular signaling. Trends Cell Biol 2017; 27 (10) 738-752
• 29 Wick W, Meisner C, Hentschel B. et al. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology 2013; 81 (17) 1515-1522
• 30 Zeng J, See AP, Phallen J. et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys 2013; 86 (02) 343-349
• 31 Park J, Kwon M, Kim KH. et al. Immune checkpoint inhibitor-induced reinvigoration of tumor-infiltrating CD8⁺ T cells is determined by their differentiation status in glioblastoma. Clin Cancer Res 2019; 25 (08) 2549-2559
• 32 Liang Y, Wang Y, Zhang Y. et al. HSPB1 facilitates chemoresistance through inhibiting ferroptotic cancer cell death and regulating NF-κB signaling pathway in breast cancer. Cell Death Dis 2023; 14 (07) 434
• 33 Long S, Peng F, Song B, Wang L, Chen J, Shang B. Heat shock protein beta 1 is a prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma. Int J Gen Med 2021; 14: 5483-5492
• 34 Peng S, Yin Y, Zhang Y, Zhu F, Yang G, Fu Y. FYN/TOPK/HSPB1 axis facilitates the proliferation and metastasis of gastric cancer. J Exp Clin Cancer Res 2023; 42 (01) 80
• 35 Huang ZC, Li H, Sun ZQ. et al. Distinct prognostic roles of HSPB1 expression in non-small cell lung cancer. Neoplasma 2018; 65 (01) 161-166
• 36 Okuno M, Adachi S, Kozawa O, Shimizu M, Yasuda I. The clinical significance of phosphorylated heat shock protein 27 (HSPB1) in pancreatic cancer. Int J Mol Sci 2016; 17 (01) 17
• 37 Deng S, Zheng Y, Mo Y. et al. Ferroptosis suppressive genes correlate with immunosuppression in glioblastoma. World Neurosurg 2021; 152: e436-e448
• 38 Gimenez M, Marie SKN, Oba-Shinjo S. et al. Quantitative proteomic analysis shows differentially expressed HSPB1 in glioblastoma as a discriminating short from long survival factor and NOVA1 as a differentiation factor between low-grade astrocytoma and oligodendroglioma. BMC Cancer 2015; 15: 481
• 39 Sabaawy HE, Ryan BM, Khiabanian H, Pine SR. JAK/STAT of all trades: linking inflammation with cancer development, tumor progression and therapy resistance. Carcinogenesis 2021; 42 (12) 1411-1419
• 40 Ridnour LA, Cheng RY, Switzer CH. et al. Molecular pathways: toll-like receptors in the tumor microenvironment: poor prognosis or new therapeutic opportunity. Clin Cancer Res 2013; 19 (06) 1340-1346
• 41 Zins K, Sioud M, Aharinejad S, Lucas T, Abraham D. Modulating the tumor microenvironment with RNA interference as a cancer treatment strategy. Methods Mol Biol 2015; 1218: 143-161
• 42 Moossavi M, Parsamanesh N, Bahrami A, Atkin SL, Sahebkar A. Role of the NLRP3 inflammasome in cancer. Mol Cancer 2018; 17 (01) 158
• 43 Crisponi L, Buers I, Rutsch F. CRLF1 and CLCF1 in Development, Health and Disease. Int J Mol Sci 2022; 23 (02) 23
• 44 Kaderbhaï C, Tharin Z, Ghiringhelli F. The role of molecular profiling to predict the response to immune checkpoint inhibitors in lung cancer. Cancers (Basel) 2019; 11 (02) 11
• 45 Neal JT, Li X, Zhu J. et al. Organoid modeling of the tumor immune microenvironment. Cell 2018; 175 (07) 1972-1988.e16
• 46 Jiao S, Subudhi SK, Aparicio A. et al. Differences in tumor microenvironment dictate T helper lineage polarization and response to immune checkpoint therapy. Cell 2019; 179 (05) 1177-1190.e13
• 47 Zhao G, Yu H, Ding L. et al. microRNA-27a-3p delivered by extracellular vesicles from glioblastoma cells induces M2 macrophage polarization via the EZH1/KDM3A/CTGF axis. Cell Death Discov 2022; 8 (01) 260
• 48 Wu J, Shen S, Liu T. et al. Chemerin enhances mesenchymal features of glioblastoma by establishing autocrine and paracrine networks in a CMKLR1-dependent manner. Oncogene 2022; 41 (21) 3024-3036
• 49 Chen Y, Song Y, Du W, Gong L, Chang H, Zou Z. Tumor-associated macrophages: an accomplice in solid tumor progression. J Biomed Sci 2019; 26 (01) 78
• 50 Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011; 480 (7378) 480-489
• 51 Gil Del Alcazar CR, Alečković M, Polyak K. Immune escape during breast tumor progression. Cancer Immunol Res 2020; 8 (04) 422-427